Orex both brands -Contrave & Mysimba are single global winner in Billion ...Yes B...$$$$$ Market.
Joke is ARNA -Belviq trying again in April 2016 with EMA, They were thrown out twice with Qysmia of Vivius.
If you are invested in Arena Pharmaceuticals (NASDAQ:ARNA), some news delivered today by competitor Orexigen (NASDAQ:OREX) is something that you need to consider. Orexigen received approval to sell Mysimba (Contrave) in Europe. This event nearly doubles the addressable market for Orexigen and allows the competitor to keep up the pressure it has here in the United States.
Arena's Belviq has not been approved in Europe though an application is slated to be filed in March of 2016. Even at that, Belviq must pass through both CHMP and then the European Commission in order to gain possible approval. With a submission in Q1 of 2016, the possible decision may not be reached until late that year or early the next.
What Arena investors need to consider is that Orexigen was already aggressive in the pricing on Contrave in the United States. In fact Arena and its partner Eisai were forced to react to the pricing strategy of the competitor and lower the price of Belviq. This put a damper on the revenue story, and in fact could have already pushed out possible milestone payments by at least a year or more. The next available milestone payment for Arena is at net sales of $250,000,000 in a year. If net sales are at $90 per bottle, it would take nearly 2.8 million bottles to achieve that level of sales. For some perspective, Eisai related sales this year are pacing to about 900,000. Sales need to increase by a factor of 3 to get to milestones. Under the old pricing of Belviq there would be about 2.3 million in sales.
Saxendra is a once-daily injection of an imitation hormone
Saxenda is a once-daily injection of an imitation of the hormone GLP-1 (glucagon-like peptide) that tells the brain when the stomach is full.
The treatment is not without risks, amongst which include pancreatitis, gall bladder disease, hypoglycemia and changes in mood and behavior.
Side effects include upset stomach, fatigue, dizziness and abdominal pain, according to a company press release.
Why not you go into those OTC trade where atleast people know its fraud and still you make lots of money.
Common Stock 12/31/2014 P 300,000 A $ 2.83 11,300,000 I See Footnote (1)
Common Stock 12/31/2014 P 4,800 A $ 2.85 11,304,800 I See Footnote (1)
Common Stock 01/02/2015 P 120,000 A $ 2.94 11,424,800 I See Footnote (1)
Common Stock 01/02/2015 P 97,900 A $ 3.05 11,522,700 I See Footnote (1)
Common Stock 01/02/2015 P 500
Names of Reporting Persons.
Conan Laughlin 10.6% (10.9% as of December 31, 2014)
** Shares reported herein for North Tide Capital, LLC (“North Tide”) represent shares which are beneficially owned by North Tide Capital Master, LP (the “Master Fund”), as reported herein, and shares which are beneficially owned by a managed account (the “Account”). North Tide serves as investment manager to both the Master Fund and the Account. Shares reported herein for Mr. Laughlin represent the above referenced shares beneficially owned by the Master Fund and the Account. Mr. Laughlin serves as the Manager of North Tide. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.